Recent studies suggest supplements like vitamin D, omega-3 and glucosamine may be associated with faster cognitive decline in specific older adult groups.
On September 10, 2026, The Washington Post reviewed recent research. This coverage investigated whether commonly used supplements like vitamin D, omega-3 fish oil and glucosamine are associated with faster cognitive decline in some older adults. The findings are observational and do not establish that these products cause dementia. They do, however, raise critical questions for anyone taking supplements to protect their memory.
The recent coverage examined three distinct lines of research. The results suggest that baseline nutrient status, existing brain health and age can influence how supplements behave in the body.
A study published in BMJ Open analyzed data from the U.S. Health and Retirement Study. The research included 5,065 Americans with a mean age of 67.5. Approximately 40 percent of these participants reported using vitamin D supplements. Over time, vitamin D supplement use was associated with slightly faster declines in overall cognition and executive function.
Notably, this association appeared only among participants who already had normal vitamin D levels. The signal was completely absent in people who had a documented deficiency or insufficiency. The researchers proposed that excess vitamin D could influence molecular signaling related to amyloid-beta production or accumulation. They presented this as a possible mechanism rather than an established explanation.
The result is highly relevant because earlier research associated low vitamin D concentrations with accelerated cognitive decline. Randomized trials testing supplementation have historically produced mixed or null results. A separate 2025 VitaMIND randomized trial investigated this exact nutrient further. That trial enrolled 620 adults with mild-to-moderate vitamin D deficiency and early cognitive decline.
Participants received 4,000 IU of vitamin D3 daily or a placebo for 24 months. The investigators found no significant benefit on executive function, working memory, verbal reasoning or daily functioning. The VitaMIND investigators concluded that supplementation did not produce cognitive benefits for this group, while noting it may still be useful for severe deficiency or other medical indications.
The recent report also highlighted an omega-3 analysis published in the Journal of Prevention of Alzheimer's Disease. This study used longitudinal data from the Alzheimer's Disease Neuroimaging Initiative. Researchers compared 273 omega-3 supplement users with 546 nonusers. Participants ranged in age from 55 to 90 and spanned from cognitively healthy individuals to those with significant disease.
Over a median follow-up of five years, reported omega-3 users showed faster deterioration across three standardized cognitive scales. These tests measured orientation, attention, memory, language and visual-spatial processing. Omega-3 users also demonstrated lower glucose metabolism in brain regions vulnerable to Alzheimer's disease. The authors noted this metabolic difference partly accounted for the observed association with cognitive decline.
The study authors concluded their results challenge the prevailing view of omega-3 as uniformly beneficial. A published response to letters about the study reaffirmed that reported use was linked to faster cognitive worsening. The response stated that reported use was associated with faster decline in FDG-PET glucose-metabolism measurements, while acknowledging the limitations already discussed in the original article.
However, the researchers acknowledged that they did not establish a causal relationship. The authors did not establish that omega-3 supplements caused the decline. The report did not provide a numerical estimate for the exact rate of decline.
Glucosamine is commonly used by middle-aged and older adults for osteoarthritis and joint symptoms. A study led by Ramon Sun at the University of Florida investigated this compound using electronic health records, mouse models and postmortem human brains. In the mouse work, Alzheimer's models showed unusually high levels of glycans, which are complex sugar structures attached to proteins and other molecules.
Genetically slowing the relevant glycan-related process improved cognitive-test performance in mice, while oral glucosamine worsened cognitive problems in the Alzheimer's mouse models. Postmortem human Alzheimer's brains also contained substantially more glycans than healthy brains, with levels in gray matter tending to rise as Alzheimer's disease advanced.
In the electronic health record analysis, glucosamine use was associated with an approximately 25 percent greater likelihood of progression from mild cognitive impairment to Alzheimer's disease or a related dementia. The report did not provide the total number of people included in the health record analysis. The findings were similarly concerning for individuals in later disease stages.
Among people who already had Alzheimer's disease or another dementia, glucosamine use was linked to an approximately 25 percent higher rate of death. The researchers suggested the supplement could worsen abnormal sugar-related modifications of proteins, but this remains an unconfirmed hypothesis. Sun noted he was stunned by the findings, calling it a compelling case for glucosamine as a potentially negative driver of neurodegeneration.
These findings carry immediate practical implications for anyone considering supplements for cognitive protection. Adults over 60 should not start taking a supplement solely because it is marketed as a brain health product. The reviewed studies confirm that these items do not preserve memory or prevent dementia for everyone.
If you currently take a prescribed supplement, do not stop abruptly based only on recent headlines. You should review the product, dose and reason for use with a physician or pharmacist. It is vital to ask if you have a documented deficiency before assuming that more of a nutrient is helpful.
Be precise during medication appointments about exactly what you take. You need to report the product name, formulation, dose and frequency to your doctor. Supplements introduce biologically active substances into your body, making them very different from harmless dietary additions. This transparency helps professionals evaluate your brain health resources and clinical needs accurately.
Finally, it is necessary to distinguish between whole foods and concentrated supplements. The Washington Post report clarified that isolated omega-3 capsules and fish-rich diets have produced different patterns in research. The recent findings apply specifically to the supplements rather than general dietary choices.
It is critical to interpret these observational findings carefully. An association in a study does not prove that a supplement causes cognitive decline. Supplement users often differ from nonusers in education, income, diet and health behaviors.
Supplement products also vary widely in dose, chemical form, purity and combination ingredients. The reviewed studies did not establish that every product or dose has the identical effect. A major confounding factor is the risk of reverse causation. People might start taking cognitive supplements because they have already noticed memory symptoms.
They could also be at an elevated baseline risk for decline. Because glucosamine use was identified through physician notes and prescription records, differences between users and nonusers could account for the entire association. Furthermore, the results apply to very specific groups. The vitamin D association only appeared in individuals with normal baseline levels.
The omega-3 analysis included a wide spectrum of cognitive health, meaning the results should not automatically generalize to every user. The glucosamine findings relied heavily on observational health records and mouse models, which do not always reproduce human Alzheimer's disease perfectly. Broad randomized trials have not demonstrated sweeping cognitive benefits from these products.
The DO-HEALTH randomized trial tested vitamin D3, omega-3s and strength training in relatively healthy older adults. The trial found no statistically significant benefit on six primary endpoints, including cognitive worsening and functional decline. The absence of a cognitive benefit does not invalidate a supplement's legitimate medical uses. The VitaMIND investigators noted that vitamin D remains valuable for severe deficiency or other specific clinical indications.
The emerging consensus points toward a highly nuanced understanding of the aging brain. The central scientific question is whether an intervention that helps a younger brain might have a different effect in an older one. Onder Albayram argued that neurological disorders are age-dependent and the brain is not metabolically static across a lifetime.
As we age, changes occur in brain metabolism, inflammatory regulation and the blood-brain barrier. The blood-brain barrier regulates the movement of nutrients, glucose and oxygen into brain tissue. Its transport systems can shift with age, meaning a substance that appears benign early in life might behave unpredictably later. The Washington Post report described several age-related changes that could alter how supplements act, including changes in biological reserve.
Marion Nestle cautioned that supplements can change biochemical markers without producing the expected clinical benefit. Navigating nutrition and brain health requires abandoning the idea of a universal preventive pill. Claims about natural ingredients should be treated as marketing language rather than established evidence for an aging brain. Maintaining cognitive health requires personalized clinical assessments rather than self-treating symptoms with commercial products.
Future research will likely focus on targeted precision rather than broad supplementation. Finding the right balance of nutrients depends entirely on individual baseline levels and existing medical conditions. Evaluating clinical options objectively is the best way to support your long-term brain aging and neuroplasticity safely.
Deciding whether to continue a specific supplement based on observational data requires careful discussion with a physician, and FitBrainLab provides the objective research necessary for those conversations. Difficulty separating established evidence from early or exaggerated health claims creates confusion, but we translate complex clinical findings so you can evaluate cognitive products safely. Explore Resources
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
